July 24, 2020 10:50 AM EDT

Sobi's high-priority rare disease drug runs into a wall at EMA

Amber Tong

Senior Editor

The EMA has rebuffed Sweden-based Sobi’s pitch for emapalumab, shooting down high hopes for a $568 million drug.

Sobi said it will request a re-examination by the regulators, which will kick off a new review process that should produce a decision by the end of the year. The antibody is designed to treat primary hemophagocytic lymphohistiocytosis in children under 18 years old by targeting interferon gamma (IFNγ).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Sobi's high-priority rare disease drug runs into a wall at EMA

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

So­bi's high-pri­or­i­ty rare dis­ease drug runs in­to a wall at EMA

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Sobi's high-priority rare disease drug runs into a wall at EMA

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal